Inflammatory bowel disease: Healthcare costs for patients who are adherent or non-adherent with infliximab therapy

Journal of Medical Economics

Volumn 17, Issue 6, 2014, Pages 384-393

  Wan, George J ^a   Kozma, Chris M ^b   Slaton, Terra L ^b   Olson, William H ^c   Feagan, Brian G ^d  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b Independent Consultant   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Adherence; Cost; Crohn's disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COLONOSCOPY; CROHN DISEASE; DRUG COST; DRUG USE; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; OUTPATIENT CARE; PATIENT COMPLIANCE; ULCERATIVE COLITIS; AGE; AGED; COST; ECONOMICS; HEALTH SERVICE; INFLAMMATORY BOWEL DISEASES; INSURANCE; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; COSTS AND COST ANALYSIS; FEMALE; GASTROINTESTINAL AGENTS; HEALTH SERVICES; HUMANS; INFLAMMATORY BOWEL DISEASES; INSURANCE CLAIM REVIEW; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84900871976     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.909436     Document Type: Article

References (21)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78
2. Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013;58:519-25
3. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008;24:319-28 (Pubitemid 351294380)
4. Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31:693-707
5. Remicade (infliximab) Prescribing Information. Horsham, PA: Janssen Biotech, Inc., Revised November 2013
6. Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013;19:1528-33
7. Bailey RA, Waters HC, Ernst FR, et al. Infliximab dosing and administration patterns in patients with Crohn's disease in a hospital outpatient setting. Am J Pharm Benefits 2011;3:e121-6
8. Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs. Adv Ther 2011;28:671-83
9. Carter CT, Waters HC, Smith DB. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn' disease. Patient Prefer Adherence 2012;6:417-26
10. Carter CT, Leher H, Smith P, et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011;17:385-92
11. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther 2009;26:936-46
12. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42: 200-9
13. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794-811
14. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
15. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937-60 (Pubitemid 39200133)
16. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262-70 (Pubitemid 43145754)
17. Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001;2:259-78
18. Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007;45:S103-7
19. Sturmer T, Rothman KJ, Glynn RJ. Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf 2006;15:698-709 (Pubitemid 44649508)
20. Gunnarsson C, Chen J, Rizzo JA, et al. The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data. J Occup Environ Med 2013;55:393-401
21. Gunnarsson C, Chen J, Rizzo JA, et al. Direct health care insurer and outof- pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci 2012;57:3080-91